# About Order Wolverine: An Editorial Digest of the BPC-157 TB-500 Record

> Order Wolverine is an independent editorial project summarizing the peer-reviewed research and FDA regulatory record on the BPC-157 TB-500 blend. Not a clinic, not a vendor, not a prescription.

An independent editorial project that keeps the BPC-157 TB-500 record the way an apothecary keeps a formulary — each component drawn as its own specimen, the measured findings set down plainly, the regulatory status kept in the margin.

## What this site is

Order Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature, and the public FDA regulatory record, on the BPC-157 TB-500 blend. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and publicly available regulatory documents.

The reading-room conceit is deliberate. We treat the Wolverine blend as what it actually is — a two-component pairing whose individual parts have measured records and whose join does not. Established single-component findings are set down as fully drawn specimens; the unproven combination and the missing human data are kept in the warm margin as open questions. The honesty is in how the record is laid out, not buried in a closing caveat.

## What "order" means here

The word order in this site's name is editorial framing, not a checkout and not a service we offer. It marks the apothecary order of the record — the formulary order, the considered ledger of what is studied and where access actually stands. It is the position this publisher occupies relative to the literature, not a claim about anything we sell or supply.

We do not offer treatment, consultation, prescription, or sales of any kind, and we do not provide medical or legal advice. Everything here is general information about the published science and the public regulatory landscape. Where the regulatory record is unsettled — as it is, with both components currently in FDA's 503A Category 2 and under a scheduled 2026 committee review — we say so plainly and never state an outcome as decided or dated.

## How we handle the evidence

Every quantitative claim on this site is tied to a numbered citation in the [full reference list with PMIDs and DOIs](/references): the peer-reviewed component studies, the 2025-2026 systematic reviews, and the FDA sources. We do not present rodent results as human expectations, we do not present a fixed-ratio vial as a validated dose, and we do not present the marketed synergy as proven — because no controlled combination study exists.

Where the literature is strong, we say so: BPC-157's transected-Achilles tendon data and VEGFR2-Akt-eNOS angiogenesis are well characterized, and Thymosin Beta-4's migration and wound-healing activity is consolidated in review. Where it is thin or absent — human combination efficacy, combination safety, a defined synergy ratio — we mark the gap rather than paper over it. That is the whole editorial posture: a careful reading of a two-part record, kept the way a specimen folio is kept.

---

The Wolverine blend kept as a kiln-fired formulary entry — BPC-157 and TB-500 set down as two annotated specimens, their measured animal-model findings inked and their unproven join left in the warm margin, with the FDA 503A and WADA record pinned to the page and nothing here prescribed or sold.